Ac-SDKP: The Anti-Fibrotic Peptide

Category: Protocols Type: Protocol Read Time: 14 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/ac-sdkp-protocol

Disclaimer: This content is for educational purposes only and is not medical advice. Ac-SDKP (Goralatide) is an investigational research compound, is NOT FDA-approved for human use, and remains a very niche, emerging area of peptide science. Consult a licensed healthcare provider before considering any peptide protocol, especially if you take blood pressure medications or have organ disease.

Overview

Ac-SDKP — N-Acetyl-Seryl-Aspartyl-Lysyl-Proline, also known by the research designation Goralatide — is a naturally occurring tetrapeptide produced in the human body. Unlike most peptides discussed in the wellness space, Ac-SDKP is endogenous: your body already makes it from a larger parent protein, thymosin beta-4 (Tβ4), via cleavage by the enzyme prolyl oligopeptidase (POP, also called prolyl endopeptidase).

It belongs to a small family of compounds being studied for anti-fibrotic and anti-inflammatory activity. Its mechanism is unusual: Ac-SDKP is a direct substrate of angiotensin-converting enzyme (ACE), the same enzyme blood pressure medications target. ACE rapidly breaks Ac-SDKP down, which has two important implications:

• Endogenous Ac-SDKP levels are tightly regulated
• ACE inhibitor drugs raise circulating Ac-SDKP — a connection that may explain some of the anti-fibrotic benefits attributed to ACEi medications beyond blood pressure control

Key Properties:

• 4 amino acid sequence (tetrapeptide)
• Naturally produced in vivo from thymosin β-4
• Very short half-life (~5 minutes) due to ACE degradation
• Anti-fibrotic, anti-inflammatory, anti-proliferative in research models
• Investigational — not approved for human therapeutic use

Mechanism of Action

Ac-SDKP appears to work through multiple converging pathways:

1. TGF-β signaling antagonism — Transforming growth factor beta is the master driver of fibrosis. Ac-SDKP appears to dampen TGF-β1 signaling in research models.
2. Smad pathway inhibition — Downstream of TGF-β, Ac-SDKP reduces phosphorylation of Smad2/3 proteins, blocking the gene-expression program that produces collagen.
3. Fibroblast-to-myofibroblast transition prevention — Myofibroblasts are the cells responsible for laying down scar tissue. Ac-SDKP appears to suppress this conversion.
4. Reduced collagen deposition — Research models show decreased collagen I and III accumulation in cardiac, renal, and pulmonary tissue.
5. Anti-inflammatory effects — Modulation of macrophage activity and inflammatory cytokine release.

The ACE relationship is mechanistically central: because ACE rapidly degrades Ac-SDKP, anything that inhibits ACE (lisinopril, enalapril, ramipril, etc.) raises endogenous Ac-SDKP. Researchers including Carretero, Rasoul, and Rhaleb have proposed that a meaningful fraction of the anti-fibrotic benefit observed with ACE inhibitors — beyond afterload reduction — may be mediated by sustained elevation of endogenous Ac-SDKP.

Tβ4 → Ac-SDKP → ACE Pathway

Understanding this pathway is the single most important concept for anyone evaluating Ac-SDKP:

Thymosin β-4 (Tβ4 / TB-500)
        |
        | cleaved by prolyl oligopeptidase
        v
   Ac-SDKP (active anti-fibrotic tetrapeptide)
        |
        | degraded by ACE
        v
   Inactive fragments

The implications are significant:

• TB-500 (Tβ4) is partially converted to Ac-SDKP in vivo. Some of the anti-fibrotic and tissue-remodeling effects attributed to TB-500 may actually be downstream Ac-SDKP activity.
• ACE inhibitor users have elevated Ac-SDKP. Direct supplementation in someone on an ACEi may produce supra-physiological exposure; this is a theoretical caution.
• Direct Ac-SDKP exposure is short-lived. A subcutaneous injection produces a brief plasma spike, then rapid ACE-mediated clearance.

This three-node pathway — Tβ4 as upstream reservoir, Ac-SDKP as active middle metabolite, ACE as the regulator — is the central mechanism story.

Conditions Researched

Ac-SDKP has been investigated in animal models and limited human studies across several fibrotic conditions:

• Cardiac fibrosis — Post-myocardial infarction remodeling, hypertensive heart disease, diabetic cardiomyopathy
• Pulmonary fibrosis — Bleomycin-induced lung fibrosis models, with implications for idiopathic pulmonary fibrosis (IPF)
• Renal fibrosis — Diabetic nephropathy, chronic kidney disease models, hypertensive nephrosclerosis
• Hepatic fibrosis — Carbon tetrachloride and other liver injury models
• Chemotherapy-induced cardiotoxicity — Particularly anthracycline (doxorubicin) damage
• Radiation fibrosis — Tissue scarring following radiotherapy
• Vascular remodeling — Inflammation-driven arterial stiffening

Important caveat: the bulk of this evidence is preclinical (animal or cell-culture). Human protocols are very limited, mostly within investigational settings.

Dosing Protocols

Human dosing data is sparse. The numbers below reflect research literature and extrapolation — not validated therapeutic dosing.

Route: Subcutaneous injection is standard given the short half-life and degradation in the GI tract. Oral and sublingual routes are not well-characterized.

Duration: Anti-fibrotic effects in research emerge over weeks to months. Short courses (under 4 weeks) are unlikely to produce meaningful structural change.

Half-Life Challenge

The single biggest pharmacological challenge with Ac-SDKP is its ~5 minute plasma half-life in subjects with normal ACE activity. This creates several practical issues:

• A single daily injection produces a brief spike, not sustained exposure
• Twice- or thrice-daily dosing only modestly improves time-above-threshold
• Continuous infusion is the gold standard in research but impractical for wellness use
• Effective AUC (area under curve) is difficult to achieve with bolus subcutaneous dosing

This pharmacokinetic limitation is the strongest argument for using TB-500 (Tβ4) as a precursor: it provides a slow, endogenous supply of Ac-SDKP via prolyl oligopeptidase cleavage, producing a more physiological exposure profile than direct injection.

It is also the strongest argument for the ACE inhibitor synergy hypothesis: blocking ACE extends Ac-SDKP half-life dramatically, potentially making lower direct doses meaningful.

TB-500 vs Direct Ac-SDKP Supplementation

For most people interested in anti-fibrotic effects, TB-500 remains the more practical entry point because it solves the half-life problem biologically.

Expected Outcomes

Realistic expectations matter with Ac-SDKP. This is not a peptide where subjective effects are noticeable within days.

Timeline:

• Weeks 1–2: No perceptible subjective effects expected
• Weeks 4–8: Possible changes in inflammatory markers in research settings
• Weeks 8–16+: Anti-fibrotic structural effects in animal models begin to be detectable on imaging or histology
• Months 4–6: Cumulative anti-fibrotic exposure in chronic dosing protocols
• Human wellness use: Largely extrapolated from animal data; subjective benefit reports are sparse and unreliable

What it is NOT:

• A recovery accelerator like BPC-157 or TB-500
• A performance or energy compound
• A fast-acting "feel something" peptide
• A substitute for approved anti-fibrotic medications

Ac-SDKP is best understood as a slow, structural intervention rather than a feel-better-fast compound. People expecting acute energy, recovery, or mood effects will be disappointed. Its value — if any — accrues silently over months in tissue architecture, not in week-to-week subjective experience.

Side Effects & Safety

Available safety data is limited but generally favorable in research contexts.

Reported / Theoretical:

• Generally well-tolerated in animal and limited human studies
• Theoretical hypotension risk via the ACE/renin-angiotensin axis
• Possible additive blood pressure effects when combined with ACE inhibitors or ARBs
• Injection site reactions (typical for SC peptides)
• Limited long-term human safety data

Contraindications:

• Pregnancy / breastfeeding — Vasoactive peptide; not studied; avoid
• Concurrent ACE inhibitor therapy — Discuss with prescriber; theoretical exposure stacking
• Active malignancy — Anti-fibrotic peptides have complex relationships with tumor stroma; caution warranted
• Severe hypotension — Theoretical risk of further blood pressure drop
• Children — Not studied

Stacking

Realistic Use Cases

Where Ac-SDKP is most plausibly relevant — always under medical guidance:

• Post-cardiac event remodeling — Adjunct interest after MI or in heart failure (research only)
• Pulmonary fibrosis adjunct — Including post-COVID lung scarring concerns and IPF
• Post-radiation tissue protection — Reducing late radiation fibrosis in irradiated fields
• Chemotherapy cardioprotection — Particularly anthracycline (doxorubicin) regimens
• Chronic kidney disease — Anti-fibrotic adjunct interest in diabetic nephropathy models
• Hepatic fibrosis — Early-stage exploratory adjunct in NAFLD/NASH research

For these contexts, Ac-SDKP is emerging and research-stage. It is not standard of care, not approved, and not a substitute for proven therapies like pirfenidone, nintedanib, ACE inhibitors, ARBs, or aldosterone antagonists where those are indicated.

Frequently Asked Questions

Q: Ac-SDKP vs TB-500 — which should I choose? A: For most people, TB-500 is the more practical choice. It provides a slow, endogenous supply of Ac-SDKP plus its own Tβ4 effects, solving the half-life problem. Direct Ac-SDKP is mostly useful in research settings.

Q: Is cardiac fibrosis prevention with Ac-SDKP real? A: In animal models and translational research — yes, reasonably well-documented. In humans as a wellness intervention — extrapolated and not validated. Standard cardioprotection (ACEi/ARB, statins, lifestyle) has far more evidence.

Q: Can I stack Ac-SDKP with my ACE inhibitor? A: This requires medical guidance. ACE inhibitors already raise your endogenous Ac-SDKP substantially. Adding exogenous Ac-SDKP could produce supra-physiological exposure with unknown consequences. Discuss with your prescriber.

Q: Is the short half-life actually a problem? A: Practically, yes. A ~5 minute half-life means bolus subcutaneous dosing produces a spike-then-clear pattern rather than sustained exposure. This is why TB-500 (a slow-release upstream source) is often preferred.

Q: Does Ac-SDKP help with long COVID lung fibrosis? A: This is an active research question. Anti-fibrotic peptides are of theoretical interest for post-COVID pulmonary scarring, but no controlled human data supports routine use. Pulmonologist consultation is essential.

Q: How long until I notice effects? A: You likely won't notice subjective effects at all. Ac-SDKP works structurally over weeks to months. If you want a peptide with noticeable acute effects, this is not the right molecule.

Q: Is Ac-SDKP FDA-approved? A: No. It is a research compound (sometimes labeled Goralatide) and is not approved for any human therapeutic use. It is sold as a research chemical and remains a very niche area.

Q: What about oral or sublingual Ac-SDKP? A: Not well-characterized. The tetrapeptide structure is unlikely to survive gastric digestion intact, and the short half-life persists even when absorbed. Subcutaneous remains the standard research route.

Related Content

• TB-500 Complete Guide
• BPC-157 Complete Guide
• BPC-157 & TB-500 Protocol
• Reconstitution Cheat Sheet
• Injection Safety Checklist

Disclaimer: This content is for educational purposes only and is not medical advice. Ac-SDKP (Goralatide) is a research compound and is NOT FDA-approved for human use. The data supporting anti-fibrotic claims is largely preclinical. Consult a licensed healthcare provider before starting any peptide protocol, particularly if you take ACE inhibitors, ARBs, or other cardiovascular medications.

Source: https://peptides.nyc/learn/ac-sdkp-protocol